BCM
CRL icon

Brasada Capital Management’s Charles River Laboratories CRL Stock Holding History

Brasada Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,000
Closed -$813K – 140
2024
Q1 		$813K Buy
+3,000
New +$716K 0.14% 106

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Brasada Capital Management's CRL Position: Q2 2024 in Review

Brasada Capital Management sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 3,000 shares — an estimated $813K sold.

Brasada Capital Management first reported a position in CRL in Q1 2024 and held it in 1 quarter. The position peaked at $813K in Q1 2024. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Brasada Capital Management reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Brasada Capital Management sold 3,000 Charles River Laboratories shares in Q2 2024, an estimated $813K.
  • Brasada Capital Management first reported a position in Charles River Laboratories in Q1 2024 and held it in 1 quarter.
  • Brasada Capital Management's Charles River Laboratories position peaked at $813K in Q1 2024.
  • 664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Brasada Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.